These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35304348)

  • 41. Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization.
    Michiels S; Barragán AM; Souris K; Poels K; Crijns W; Lee JA; Sterpin E; Nuyts S; Haustermans K; Depuydt T
    Radiother Oncol; 2018 Jul; 128(1):161-166. PubMed ID: 28951008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Physical and Radiobiological Evaluation of Accelerated Intensity Modulated Radiotherapy for Locally Advanced Head and Neck Cancer and Comparison with Short-Term Clinical Outcomes.
    Buchapudi RR; Manickam R; M R AK; C R TP; Chandraraj V; Pyakuryal A; Narayanasamy G
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2463-2470. PubMed ID: 31450921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer.
    Eisbruch A; Ship JA; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Hogikyan ND; Anzai Y; Marsh LH; Ten Haken RK; Wolf GT
    World J Surg; 2003 Jul; 27(7):832-7. PubMed ID: 14509515
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer.
    Dawson LA; Anzai Y; Marsh L; Martel MK; Paulino A; Ship JA; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1117-26. PubMed ID: 10725621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study.
    Wu Q; Manning M; Schmidt-Ullrich R; Mohan R
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):195-205. PubMed ID: 10656393
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proton therapy and oral mucositis in oral & oropharyngeal cancers: outcomes, dosimetric and NTCP benefit.
    Nangia S; Gaikwad U; Noufal MP; Sawant M; Wakde M; Mathew A; Chilukuri S; Sharma D; Jalali R
    Radiat Oncol; 2023 Jul; 18(1):121. PubMed ID: 37468950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differences between planned and delivered dose for head and neck cancer, and their consequences for normal tissue complication probability and treatment adaptation.
    Heukelom J; Kantor ME; Mohamed ASR; Elhalawani H; Kocak-Uzel E; Lin T; Yang J; Aristophanous M; Rasch CR; Fuller CD; Sonke JJ
    Radiother Oncol; 2020 Jan; 142():100-106. PubMed ID: 31431381
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
    Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
    Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intentional avoidance of the esophagus using intensity modulated radiation therapy to reduce dysphagia after palliative thoracic radiation.
    Granton PV; Palma DA; Louie AV
    Radiat Oncol; 2017 Jan; 12(1):27. PubMed ID: 28122566
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy.
    Sapir E; Tao Y; Feng F; Samuels S; El Naqa I; Murdoch-Kinch CA; Feng M; Schipper M; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):354-361. PubMed ID: 27473816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Target volume definition for head and neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines.
    Guerrero Urbano MT; Clark CH; Kong C; Miles E; Dearnaley DP; Harrington KJ; Nutting CM; PARSPORT Trial Management Group
    Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):604-13. PubMed ID: 17706404
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Swallowing sparing intensity modulated radiotherapy (SW-IMRT) in head and neck cancer: Clinical validation according to the model-based approach.
    Christianen ME; van der Schaaf A; van der Laan HP; Verdonck-de Leeuw IM; Doornaert P; Chouvalova O; Steenbakkers RJ; Leemans CR; Oosting SF; van der Laan BF; Roodenburg JL; Slotman BJ; Bijl HP; Langendijk JA
    Radiother Oncol; 2016 Feb; 118(2):298-303. PubMed ID: 26700602
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Fried D; Price A; Amdur RJ; Mendenhall W; Lu C; Das S; Sheets N; Marks L; Mavroidis P
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1022-1027. PubMed ID: 28721884
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reducing Xerostomia by Comprehensive Protection of Salivary Glands in Intensity-Modulated Radiation Therapy with Helical Tomotherapy Technique for Head-and-Neck Cancer Patients: A Prospective Observational Study.
    Teng F; Fan W; Luo Y; Ju Z; Gong H; Ge R; Tong F; Zhang X; Ma L
    Biomed Res Int; 2019; 2019():2401743. PubMed ID: 31380414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy.
    Schwartz DL; Hutcheson K; Barringer D; Tucker SL; Kies M; Holsinger FC; Ang KK; Morrison WH; Rosenthal DI; Garden AS; Dong L; Lewin JS
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1356-65. PubMed ID: 20646872
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SPECT/CT-guided elective nodal irradiation for head and neck cancer: Estimation of clinical benefits using NTCP models.
    de Veij Mestdagh PD; Janssen T; Lamers E; Carbaat C; Hamming-Vrieze O; Vogel WV; Sonke JJ; Al-Mamgani A
    Radiother Oncol; 2019 Jan; 130():18-24. PubMed ID: 30087057
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of radiation dose to pharyngeal constrictor muscles on late dysphagia and quality of life in patients with locally advanced oropharyngeal carcinoma.
    Mogadas S; Busch CJ; Pflug C; Hanken H; Krüll A; Petersen C; Tribius S
    Strahlenther Onkol; 2020 Jun; 196(6):522-529. PubMed ID: 32006068
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Prospective Study of Mucosal Sparing Radiation Therapy in Resected Oropharyngeal Cancer Patients.
    Anderson JD; DeWees TA; Ma DJ; Nagel TH; Van Abel KM; Moore EJ; Rwigema JCM; Routman DM; Wittich MN; McGee LA; Hayden RE; Foote RL; Golafshar M; Gamez ME; Lester SC; Anand A; Crujido LR; Halyard MY; Hinni ML; Patel SH
    Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):192-201. PubMed ID: 36309077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.